These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26743172)

  • 1. A Generic Platform for Cellular Screening Against Ubiquitin Ligases.
    Maculins T; Carter N; Dorval T; Hudson K; Nissink JW; Hay RT; Alwan H
    Sci Rep; 2016 Jan; 6():18940. PubMed ID: 26743172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approach for characterizing ubiquitin E3 ligase function.
    Marblestone JG; Suresh Kumar KG; Eddins MJ; Leach CA; Sterner DE; Mattern MR; Nicholson B
    J Biomol Screen; 2010 Dec; 15(10):1220-8. PubMed ID: 20864734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases.
    Tian M; Zeng T; Liu M; Han S; Lin H; Lin Q; Li L; Jiang T; Li G; Lin H; Zhang T; Kang Q; Deng X; Wang HR
    J Biol Chem; 2019 Feb; 294(8):2880-2891. PubMed ID: 30587574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A High-Throughput Screening Strategy for Development of RNF8-Ubc13 Protein-Protein Interaction Inhibitors.
    Weber E; Rothenaigner I; Brandner S; Hadian K; Schorpp K
    SLAS Discov; 2017 Mar; 22(3):316-323. PubMed ID: 27909234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput Screening of HECT E3 Ubiquitin Ligases Using UbFluor.
    Foote PK; Krist DT; Statsyuk AV
    Curr Protoc Chem Biol; 2017 Sep; 9(3):174-195. PubMed ID: 28910856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway.
    De Cesare V; Johnson C; Barlow V; Hastie J; Knebel A; Trost M
    Cell Chem Biol; 2018 Sep; 25(9):1117-1127.e4. PubMed ID: 30017913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
    Liu L; Wong CC; Gong B; Yu J
    Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of approaches for screening for ubiquitin ligase inhibitors.
    Sun Y
    Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy.
    Rossi M; Rotblat B; Ansell K; Amelio I; Caraglia M; Misso G; Bernassola F; Cavasotto CN; Knight RA; Ciechanover A; Melino G
    Cell Death Dis; 2014 May; 5(5):e1203. PubMed ID: 24787015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins.
    Marblestone JG; Larocque JP; Mattern MR; Leach CA
    Biochim Biophys Acta; 2012 Nov; 1823(11):2094-7. PubMed ID: 22721718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted modulation of E3 ligases using engineered ubiquitin variants.
    LeBlanc N; Mallette E; Zhang W
    FEBS J; 2021 Apr; 288(7):2143-2165. PubMed ID: 32867007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Ubiquitination Platform Identifies Methyl Ellipticiniums as Ubiquitin Ligase Inhibitors.
    Wilson BAP; Voeller D; Smith EA; Wamiru A; Goncharova EI; Liu G; Lipkowitz S; O'Keefe BR
    SLAS Discov; 2021 Aug; 26(7):870-884. PubMed ID: 33882749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays.
    Andrews PS; Schneider S; Yang E; Michaels M; Chen H; Tang J; Emkey R
    Assay Drug Dev Technol; 2010 Aug; 8(4):471-87. PubMed ID: 20804422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive ubiquitin E2 profiling of ten ubiquitin E3 ligases.
    Marblestone JG; Butt S; McKelvey DM; Sterner DE; Mattern MR; Nicholson B; Eddins MJ
    Cell Biochem Biophys; 2013 Sep; 67(1):161-7. PubMed ID: 23695783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of E3 ubiquitin ligases by homotypic and heterotypic assembly.
    Balaji V; Hoppe T
    F1000Res; 2020; 9():. PubMed ID: 32076548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOIL-1, an atypical E3 ligase that controls MyD88 signalling by forming ester bonds between ubiquitin and components of the Myddosome.
    Cohen P; Kelsall IR; Nanda SK; Zhang J
    Adv Biol Regul; 2020 Jan; 75():100666. PubMed ID: 31615747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput screening for inhibitors of the e3 ubiquitin ligase APC.
    Huang J; Sheung J; Dong G; Coquilla C; Daniel-Issakani S; Payan DG
    Methods Enzymol; 2005; 399():740-54. PubMed ID: 16338393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery.
    Auger KR; Copeland RA; Lai Z
    Methods Enzymol; 2005; 399():701-17. PubMed ID: 16338390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitin-mediated degradation of Rpn4 is controlled by a phosphorylation-dependent ubiquitylation signal.
    Ju D; Xu H; Wang X; Xie Y
    Biochim Biophys Acta; 2007 Nov; 1773(11):1672-80. PubMed ID: 17532487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.